Name | SR9243 |
Synonyms | SR9243 CS-1645 SR 9243 SR-9243 N-(3-bromophenethyl)-2,4,6-trimethyl-N-((3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide N-[2-(3-Bromophenyl)ethyl]-2,4,6-trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]benzenesulfonamide Benzenesulfonamide, N-[2-(3-bromophenyl)ethyl]-2,4,6-trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]- |
CAS | 1613028-81-1 |
Molecular Formula | C31H32BrNO4S2 |
Molar Mass | 626.62 |
Density | 1.347±0.06 g/cm3(Predicted) |
Melting Point | 154-155°C |
Boling Point | 786.3±70.0 °C(Predicted) |
Solubility | 10 mM in DMSO |
Appearance | solid |
Color | White |
pKa | -6.90±0.70(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
In vitro study | In HEK293 cells expressing LXRs, SR9243 inhibits LXR activation by enhancing LXR-co-repressor aggregation. In various cancer cell types, SR9243 reduces cancer cell activity, induces apoptotic cell death, and sensitizes cancer cells to chemotherapy. |
In vivo study | SR9243 (60 mg/kg, I. p.) inhibits LXR-dependent fat synthase gene expression and tumor growth in Ob/Ob mice fed a high-fat diet. |
HS Code | 29350090 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.596 ml | 7.979 ml | 15.959 ml |
5 mM | 0.319 ml | 1.596 ml | 3.192 ml |
10 mM | 0.16 ml | 0.798 ml | 1.596 ml |
5 mM | 0.032 ml | 0.16 ml | 0.319 ml |
biological activity | SR9243 is a potent and selective inverse agonist of LXR. |
Target | Value |